SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 237 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $377,990 | -94.1% | 14,010 | -92.5% | 0.00% | -100.0% |
| Q1 2024 | $6,380,413 | +2050.7% | 187,404 | +1719.3% | 0.00% | – |
| Q4 2023 | $296,669 | -19.5% | 10,301 | -22.9% | 0.00% | – |
| Q3 2023 | $368,579 | -54.1% | 13,364 | -50.4% | 0.00% | -100.0% |
| Q2 2023 | $803,472 | +7.1% | 26,917 | +31.2% | 0.00% | 0.0% |
| Q1 2023 | $750,534 | -22.8% | 20,512 | -24.9% | 0.00% | 0.0% |
| Q4 2022 | $972,670 | +23.0% | 27,330 | +17.8% | 0.00% | 0.0% |
| Q3 2022 | $791,000 | +54.5% | 23,196 | +29.9% | 0.00% | 0.0% |
| Q2 2022 | $512,000 | -6.9% | 17,852 | +5.1% | 0.00% | 0.0% |
| Q1 2022 | $550,000 | +128.2% | 16,991 | +119.0% | 0.00% | – |
| Q2 2021 | $241,000 | -24.2% | 7,758 | -48.7% | 0.00% | -100.0% |
| Q3 2020 | $318,000 | -86.5% | 15,111 | -70.7% | 0.00% | -75.0% |
| Q1 2018 | $2,363,000 | +1058.3% | 51,590 | +538.4% | 0.00% | – |
| Q4 2016 | $204,000 | – | 8,081 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |